EUVIMEDEUVIMED entdecken
Crossref

Discovery of a Chiral 2,4-Substituted Pyrrolo[2,3- d ]pyrimidine as a Potent, Selective, and Orally Bioavailable LRRK2 Inhibitor

Omar Moukha-Chafiq iD, Tuyana Malankhanova, Jacob Valiyaveettil, Vandana Gupta, Hollis Kezar, Sixue Zhang, Theresa H Nguyen, Shuklendu Karyakarte, Wei Zhang, Soumendranath Bhakat, Robert A Galemmo, Subramaniam Ananthan und 7 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c02473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Omar Moukha-Chafiq und 18 weiteren Autor:innen. Beteiligte Einrichtung: Scientific Platforms Division, Southern Research, Birmingham, Alabama 35205, United States. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Pyrimidines, Protein Kinase Inhibitors, Pyrroles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: University of Alabama at Birmingham, Southern Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhibition of leucine-rich repeat kinase (LRRK2) activity with small molecules has emerged as a potential novel therapeutic target for Parkinson's disease (PD). We have previously reported the identification of SRI-29132 as a potent LRRK2 inhibitor, but the presence of a 6-thioether moiety, which is an oxidative liability, precludes its further development. Herein, we report another hit-to-lead optimization study that led to the discovery of the chiral 2,4-substituted pyrrolo[2,3-d]pyrimidine series as potent LRRK2 inhibitors. Our lead analog 6, derived from a high-throughput screening hit SRI-31255, exhibits excellent LRRK2 inhibition activity and, high selectivity across the kinome. Further, the molecule has acceptable absorption, distribution, metabolism, and excretion (ADME), and pharmacokinetic (PK) properties, as well as brain permeability and no off-target liabilities. This new class of compounds serves as a novel series for further study in the development of LRRK2 inhibitors for therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2PyrimidinesProtein Kinase InhibitorsPyrrolesHumansAnimalsStructure-Activity RelationshipAdministration, OralBiological AvailabilityRatsDrug DiscoveryMale

Substanzen

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2PyrimidinesProtein Kinase InhibitorsLRRK2 protein, humanPyrrolesPyrrolo(2,3-d)pyrimidine

Autor:innen und Institutionen

  • Scientific Platforms Division, Southern Research, Birmingham, Alabama 35205, United States.
  • Department of Pharmacology, Duke University School of Medicine, Durham, North Carolina 27710, United States.
  • System Pharmacology AI Research Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35233, United States.

ORCID-Profile: Omar Moukha-Chafiq, Corinne E Augelli-Szafran

Förderung

  • University of Alabama at Birmingham
  • Southern Research

Zitieren

APA

Moukha-Chafiq, O., Malankhanova, T., Valiyaveettil, J., Gupta, V., Kezar, H., Zhang, S., Nguyen, T. H., Karyakarte, S., Zhang, W., Bhakat, S., Galemmo, R. A., Ananthan, S., Manuvakhova, A., Ross, L. I., Maddry, J. A., Bostwick, R., Suto, M. J., West, A., & Augelli-Szafran, C. E. (2025). Discovery of a Chiral 2,4-Substituted Pyrrolo[2,3- d ]pyrimidine as a Potent, Selective, and Orally Bioavailable LRRK2 Inhibitor. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02473

Vancouver

Moukha-Chafiq O, Malankhanova T, Valiyaveettil J, Gupta V, Kezar H, Zhang S, et al. Discovery of a Chiral 2,4-Substituted Pyrrolo[2,3- d ]pyrimidine as a Potent, Selective, and Orally Bioavailable LRRK2 Inhibitor. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02473

BibTeX
@article{MoukhaChafiq2025,
  author = {Moukha-Chafiq, Omar and Malankhanova, Tuyana and Valiyaveettil, Jacob and Gupta, Vandana and Kezar, Hollis and Zhang, Sixue and Nguyen, Theresa H and Karyakarte, Shuklendu and Zhang, Wei and Bhakat, Soumendranath and Galemmo, Robert A and Ananthan, Subramaniam and Manuvakhova, Anna and Ross, Larry I and Maddry, Joseph A and Bostwick, Robert and Suto, Mark J and West, Andrew and Augelli-Szafran, Corinne E},
  title = {Discovery of a Chiral 2,4-Substituted Pyrrolo[2,3- d ]pyrimidine as a Potent, Selective, and Orally Bioavailable LRRK2 Inhibitor},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c02473}
}
Kostenlos starten →